Summary & Overview
HCPCS Level II J7612: Levalbuterol Inhalation Solution, DME 0.5 mg
HCPCS Level II code J7612 covers levalbuterol inhalation solution, an FDA-approved, non-compounded concentrated product (0.5 mg) intended for administration through durable medical equipment (DME). This code matters nationally as it governs billing for a commonly used bronchodilator delivery form across home and outpatient settings, affecting coverage, access to inhaled therapy, and DME supplier reimbursement. Payers evaluated in this context include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise explanation of the clinical role of levalbuterol delivered via nebulizer, the typical sites of service, and the service type associated with J7612. The publication outlines payer coverage patterns and benchmarks, common billing modifiers and administrative considerations (listed separately), and the clinical context in which this inhalation solution is used. It also highlights policy and coding considerations that influence reimbursement and billing workflows for providers and DME suppliers. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J7612 describes levalbuterol inhalation solution, an FDA-approved final product in concentrated form (0.5 mg) intended for administration through durable medical equipment (DME). The code represents a prescription bronchodilator solution used to treat bronchospasm and related respiratory conditions when delivered via inhalation.
Service type: Inhalation medication administered via DME (nebulizer solution)
Typical site of service: Home or outpatient settings where durable medical equipment (nebulizers) is used, including home health and outpatient clinics that supply or bill for inhalation solutions administered through DME.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or pediatric patient with acute bronchodilator-responsive airway obstruction such as asthma exacerbation or COPD exacerbation who requires inhaled short-acting beta-agonist therapy delivered via a durable medical equipment (DME) nebulizer. The patient presents to an outpatient infusion clinic, respiratory therapy suite, emergency department, or skilled nursing facility with increased wheeze, dyspnea, or decreased peak flow. A clinician (pulmonologist, emergency physician, or primary care provider) orders nebulized levalbuterol J7612 to be administered through the facility’s DME nebulizer. Respiratory therapy or nursing verifies the medication vial, prepares the concentrated 0.5 mg levalbuterol solution per manufacturer instructions, connects it to the nebulizer mouthpiece or mask, and administers treatments typically every 20 minutes for up to three doses or as clinically indicated. Treatment documentation includes indication, drug name and HCPCS J7612, dose/concentration, route (inhalation via DME), number of units administered, patient response (wheezing, work of breathing, oxygen saturation), and any adverse events. Billing is submitted using HCPCS Level II code J7612 with applicable modifiers to indicate circumstances such as multiple procedure, service location, or emergency.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|